# To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer

Source: https://onco.cc/trials/nct06808412/  
OnCo record `nct06808412` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by xiaohua li, now recruiting.

## Summary

To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer is a phase 2, interventional study registered as NCT06808412 by xiaohua li, with a registry enrolment figure of 118 participants, started 2024-07-05 and due to reach its primary completion in 2025-05-05. Interventions recorded: sintilimab combined with bevacizumab and XELOX. Conditions listed: Rcctal Cancer. Primary outcome: assess the pathological complete response (pCR) rate of tumors after neoadjuvant chemotherapy for rectal cancer using sintilimab combined with bevacizumab. Colorectal eligibility wording from the registry: "Rectal cancer patients who have previously received perioperative XELOX regimen treatment". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06808412
- Phase: 2
- Setting: A Study on the Efficacy and Safety of Sintilimab Combined With Bevacizumab in Perioperative Neoadjuvant Chemotherapy for Locally Advanced Low Rectal Cancer
- Sponsor: xiaohua li
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT06808412: https://clinicaltrials.gov/study/NCT06808412

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06808412.json